Telomir Pharmaceuticals ( NASDAQ: TELO ) announced on Wednesday, preclinical findings demonstrating that Telomir-1 reduces tumor size by approximately 50% in a prostate cancer animal model using highly aggressive human prostate cancer cells. It was found that Telomir-1 actively suppresses cancer growth rather.
Back to Health Page
